Heart rate as a predictor of cardiovascular risk

European Journal of Clinical Investigation

Volumn 48, Issue 3, 2018, Pages

  Tadic, Marijana ^a   Cuspidi, Cesare ^b   Grassi, Guido ^b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

heart failure; heart rate; hypertension; ischaemic heart disease; mortality; stroke

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORBIDITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ELEVATED BLOOD PRESSURE; EMBASE; FOLLOW UP; HEART FAILURE; HEART RATE; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MALIGNANT NEOPLASM; MEDLINE; METABOLIC DISORDER; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESTING HEART RATE; REVIEW; ADOLESCENT; ADULT; AGED; FEMALE; GLOBAL HEALTH; HEART ARRHYTHMIA; HYPERTENSION; MALE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; GLOBAL HEALTH; HEART FAILURE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; STROKE; YOUNG ADULT;

EID: 85041626922     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12892     Document Type: Review

References (69)

1. Dyer AR, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol. 1980;112:736-749.
2. Hansen TW, Thijs L, Boggia J, et al. Prognostic value of ambulatory heart rate revisited in 6928 subjects from 6 populations. Hypertension. 2008;52:229-235.
3. Alhalabi L, Singleton MJ, Oseni AO, Shah AJ, Zhang ZM, Soliman EZ. Relation of higher resting heart rate to risk of cardiovascular versus non-cardiovascular death. Am J Cardiol. 2017;119:1003-1007.
4. Zhang D, Shen X, Qi X. Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis. CMAJ. 2016;188:E53-E63.
5. Wang A, Chen S, Wang C, et al. Resting heart rate and risk of cardiovascular diseases and all-cause death: the Kailuan study. PLoS ONE. 2014;9:e110985.
6. Woodward M, Webster R, Murakami Y, et al. The association between resting heart rate, cardiovascular disease and mortality: evidence from 112 680 men and women in 12 cohorts. Eur J Prev Cardiol. 2014;21:719-726.
7. Aune D, Sen A, ó’Hartaigh B, et al. Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality - A systematic review and dose-response meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2017;27:504-517.
8. van Kruijsdijk RC, van der Graaf Y, Bemelmans RH, Nathoe HM, Peeters PH, Visseren FL, SMART Study Group. The relation between resting heart rate and cancer incidence, cancer mortality and all-cause mortality in patients with manifest vascular disease. Cancer Epidemiol. 2014;38:715-721.
9. Jiang X, Liu X, Wu S, et al. Metabolic syndrome is associated with and predicted by resting heart rate: a cross-sectional and longitudinal study. Heart. 2015;101:44-49.
10. Palatini P. Heart rate and the cardiometabolic risk. Curr Hypertens Rep. 2013;15:253-259.
11. White DW, Raven PB. Autonomic neural control of heart rate during dynamic exercise: revisited. J Physiol. 2014;592:2491-2500.
12. Eppinga RN, Hagemeijer Y, Burgess S, et al. Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality. Nat Genet. 2016;48:1557-1563.
13. Jensen MT, Wod M, Galatius S, Hjelmborg JB, Jensen GB, Christensen K. Heritability of resting heart rate and association with mortality in middle-aged and elderly twins. Heart. 2018;104:30-36.
14. den Hoed M, Eijgelsheim M, Esko T, et al. Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet. 2013;45:621-631.
15. Benetos A, Rudnichi A, Thomas F, Safar M, Guize L. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension. 1999;33:44-52.
16. Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens. 2004;17:1005-1010.
17. Pittaras AM, Faselis C, Doumas M, et al. Heart rate at rest, exercise capacity, and mortality risk in veterans. Am J Cardiol. 2013;112:1605-1609.
18. Saxena A, Minton D, Lee DC, et al. Protective role of resting heart rate on all-cause and cardiovascular disease mortality. Mayo Clin Proc. 2013;88:1420-1426.
19. Grassi G, Seravalle G, Mancia G. Sympathetic activation in cardiovascular disease: evidence, clinical impact and therapeutic implications. Eur J Clin Invest. 2015;45:1367-1375.
20. Palatini P, Dorigatti F, Zaetta V, et al. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens. 2006;24:1873-1880.
21. Kim JR, Kiefe CI, Liu K, Williams OD, Jacobs DR Jr, Oberman A. Heart rate and subsequent blood pressure in young adults: the CARDIA study. Hypertension. 1999;33:640-646.
22. Palatini P, Reboldi G, Beilin LJ, et al. Masked tachycardia. A predictor of adverse outcome in hypertension. J Hypertens. 2017;35:487-492.
23. Palatini P, Reboldi G, Beilin LJ, et al. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol. 2013;168:1490-1495.
24. Wang A, Liu X, Guo X, et al. Resting heart rate and risk of hypertension: results of the Kailuan cohort study. J Hypertens. 2014;32:1600-1605.
25. Böhm M, Schumacher H, Leong D, et al. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension. 2015;65:651-661.
26. Williams B, Lacy PS, CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFÉ (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J Am Coll Cardiol. 2009;54:705-713.
27. Fischer-Rasokat U, Honold J, Lochmann D, et al. Ivabradine therapy to unmask heart rate-independent effects of β-blockers on pulse wave reflections. Clin Res Cardiol. 2014;103:487-494.
28. Tomiyama H, Hashimoto H, Tanaka H, et al. Synergistic relationship between changes in the pulse wave velocity and changes in the heart rate in middle-aged Japanese adults: a prospective study. J Hypertens. 2010;28:687-694.
29. Messerli FH, Rimoldi SF, Bangalore S, Bavishi C, Laurent S. When an increase in central systolic pressure overrides the benefits of heart rate lowering. J Am Coll Cardiol. 2016;68:754-762.
30. Custodis F, Reil JC, Laufs U, Böhm M. Heart rate: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum. J Cardiol. 2013;62:183-187.
31. Nanchen D, Stott DJ, Gussekloo J, et al. Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study. Eur J Heart Fail. 2013;15:581-588.
32. Nanchen D, Leening MJ, Locatelli I, et al. Resting heart rate and the risk of heart failure in healthy adults: the Rotterdam the Rotterdam Study. Circ Heart Fail. 2013;6:403-410.
33. Opdahl A, Ambale Venkatesh B, Fernandes VR, et al. Resting heart rate as predictor for left ventricular dysfunction and heart failure: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63:1182-1189.
34. Khan H, Kunutsor S, Kalogeropoulos AP, et al. Resting heart rate and risk of incident heart failure: three prospective cohort studies and a systematic meta-analysis. J Am Heart Assoc. 2015;4:e001364.
35. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784-794.
36. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBISII Trial. Circulation. 2001;103:1428-1433.
37. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886-894.
38. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875-885.
39. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807-816.
40. Kotecha D, Holmes J, Krum H, et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235-2243.
41. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2017;39:26-35 https://doi.org/10.1093/eurheartj/ehx564.
42. Kotecha D, Flather MD, Altman DG, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol. 2017;69:2885-2896.
43. Böhm M, Borer JS, Camm J, et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. Eur J Heart Fail. 2015;17:518-526.
44. Cannon JA, Shen L, Jhund PS, et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. Eur J Heart Fail. 2016;18:1021-1031.
45. Komajda M, Isnard R, Cohen-Solal A, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19:1495-1503.
46. Simpson J, Castagno D, Doughty RN, et al. Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. Eur J Heart Fail. 2015;17:1182-1191.
47. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001;104:1477-1482.
48. Zhang Y, Wu NQ, Xu RX, et al. Elevated resting heart rate is associated with the severity of coronary artery disease in non-treated patients who underwent coronary angiography: potential role of lipoprotein subfractions. Arch Physiol Biochem. 2017;123:356-363.
49. Zuanetti G, Hernandes-Bernal F, Rossi A, Comerio G, Paolucci G, Maggioni AP. Relevance of heart rate as a prognostic factor in myocardial infarction: the GISSI experience. Eur Heart J. 1999;1(Suppl. H):H52-H57.
50. Zhang D, Wang W, Li F. Association between resting heart rate and coronary artery disease, stroke, sudden death and non-cardiovascular diseases: a meta-analysis. CMAJ. 2016;188:E384-E392.
51. Wang EY, Dixson J, Schiller NB, Whooley MA. Causes and predictors of death in patients with coronary heart disease (from the Heart and Soul study). Am J Cardiol. 2017;119:27-34.
52. Fox K, Bousser MG, Amarenco P, et al. Heart rate is a prognostic risk factor for myocardial infarction: a post hoc analysis in the PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with history oF ischemic strOke or tRansient ischeMic attack) study population. Int J Cardiol. 2013;168:3500-3505.
53. Wang SL, Wang CL, Wang PL, et al. Resting heart rate associates with one-year risk of major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention. Exp Biol Med (Maywood). 2016;241:478-484.
54. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091-1099.
55. Custodis F, Gertz K, Balkaya M, et al. Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice. Stroke. 2011;42:1742-1749.
56. Böhm M, Cotton D, Foster L, et al. Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. Eur Heart J. 2012;33:2804-2812.
57. Zhong C, Zhong X, Xu T, et al. Combined effects of hypertension and heart rate on the risk of stroke and coronary heart disease: a population-based prospective cohort study among Inner Mongolians in China. Hypertens Res. 2015;38:883-888.
58. Qiu M, Sato S, Zheng D, et al. Admission heart rate predicts poor outcomes in acute intracerebral hemorrhage: the intensive blood pressure reduction in acute cerebral hemorrhage trial studies. Stroke. 2016;47:1479-1485.
59. Yu J, Dai L, Zhao Q, et al. Association of cumulative exposure to resting heart rate with risk of stroke in general population: The Kailuan cohort study. J Stroke Cerebrovasc Dis. 2017;26:2501-2509.
60. Nolte CH, Erdur H, Grittner U, et al. Impact of heart rate on admission on mortality and morbidity in acute ischaemic stroke patients – results from VISTA. Eur J Neurol. 2016;23:1750-1756.
61. Böhm M, Schumacher H, Schmieder RE, et al. Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. J Intern Med. 2015;278:38-49.
62. Iseki K, Nakai S, Yamagata K, Tsubakihara Y, Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy. Tachycardia as a predictor of poor survival in chronic haemodialysis patients. Nephrol Dial Transplant. 2011;26:963-969.
63. Brotman DJ, Bash LD, Qayyum R, et al. Heart rate variability predicts ESRD and CKD-related hospitalization. J Am Soc Nephrol. 2010;21:1560-1570.
64. Inoue T, Iseki K, Iseki C, Ohya Y, Kinjo K, Takishita S. Heart rate as a risk factor for developing chronic kidney disease: longitudinal analysis of a screened cohort. Clin Exp Nephrol. 2009;13:487-493.
65. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-1918.
66. Jensen MT, Marott JL, Lange P, et al. Resting heart rate is a predictor of mortality in COPD. Eur Respir J. 2013;42:341-349.
67. Warnier MJ, Rutten FH, de Boer A, Hoes AW, De Bruin ML. Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumonia. PLoS ONE. 2014;9:e105152.
68. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-887.
69. Jouven X, Escolano S, Celermajer D, et al. Heart rate and risk of cancer death in healthy men. PLoS ONE. 2011;6:e21310.